Daniel O’Connor - Advaxis
Daniel O’Connor has been appointed Chairman of the Board at clinical-stage biotech Advaxis. O’Connor takes over from Thomas Moore who will remain a consultant to the company.
“The Company is now entering a transformational phase, and Dan’s appointment as CEO is the outcome of Tom and the Board’s succession planning initiatives over the past year in preparation for this important time,” said Dr. James Patton, Chairman of the Audit Committee, who too has a new role, having been elected Non-Executive Chairman of the Board.
